Moderna Stock (MRNA) Faces Cash Crunch Ahead of Analyst Day
Moderna stock enters Thursday's analyst day under significant pressure. Slowing revenue, pipeline setbacks, and a dwindling cash reserve compel the company to demonstrate its path to breakeven before liquidity tightens further.
The biotech firm's challenges highlight the precarious balance between innovation funding and financial sustainability in high-growth sectors. Market scrutiny intensifies as investors weigh Moderna's ability to pivot beyond its COVID-19 vaccine windfall.